Drug recall · November 28, 2018
IRBESARTAN Tablets recall
Why: CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodiethylamine (NDEA) in product.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
IRBESARTAN Tablets, USP 75 mg 90-count bottle, Rx Only, Manufactured by: SciGen Pharmaceuticals, Inc. Hauppauge, NY 11788, Distributed by: GSMS, Incorporated, Camarillo, CA 93012, USA, NDC 60429-640-90.
- Lots / codes
Lot Numbers: B160003; Exp. 09/19 B160004; Exp. 09/19
- Quantity
- 2,439 bottles
- Company
- Golden State Medical Supply Inc., Camarillo, CA
- Distribution
- Product was distributed throughout the United States.
- Initiated
- November 2, 2018 · Voluntary: Firm initiated
- Classified
- November 20, 2018
- Reported
- November 28, 2018
- Ended
- September 16, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Irbesartan
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.